*In Metastatic Renal cell cancer : Sutent Response rate was 38%
with median response duration 53 weeks
most of the responses were observed in 12 weeks (European Journal)
*In Metastatic HER-2 positive Breast cancers, Adding chemotherapy to Herceptin increases the response Rate from 15-26% to 60-70%, weekly Taxol +/- Carboplatin is one of the option aside from Vinorelbie and Taxotere with improvement of both the one year and overall survival!
*Lapatinib, a dual EGFR-1 and Her-2 Tyrosine Kinase inhibitor, when combined to Capecitabine only increase (more likely double) for sure progression free survival. The overall survival could not be proven because of cross-over! (ASCO)
No comments:
Post a Comment